Citations (110)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Saeed Alqahtani, Loqman A Mohamed & Amal Kaddoumi. (2013) Experimental models for predicting drug absorption and metabolism. Expert Opinion on Drug Metabolism & Toxicology 9:10, pages 1241-1254.
Read now
Read now
Pascal Espié, Dominique Tytgat, Maria-Laura Sargentini-Maier, Italo Poggesi & Jean-Baptiste Watelet. (2009) Physiologically based pharmacokinetics (PBPK). Drug Metabolism Reviews 41:3, pages 391-407.
Read now
Read now
Nikoletta Fotaki. (2009) Pros and cons of methods used for the prediction of oral drug absorption. Expert Review of Clinical Pharmacology 2:2, pages 195-208.
Read now
Read now
Andrea N Edginton, Frank-Peter Theil, Walter Schmitt & Stefan Willmann. (2008) Whole body physiologically-based pharmacokinetic models: their use in clinical drug development. Expert Opinion on Drug Metabolism & Toxicology 4:9, pages 1143-1152.
Read now
Read now
Stefan S De Buck & Claire E Mackie. (2007) Physiologically based approaches towards the prediction of pharmacokinetics: in vitro–in vivo extrapolation. Expert Opinion on Drug Metabolism & Toxicology 3:6, pages 865-878.
Read now
Read now
P. J. Lowe, Y. Hijazi, O. Luttringer, H. Yin, R. Sarangapani & D. Howard. (2007) On the anticipation of the human dose in first-in-man trials from preclinical and prior clinical information in early drug development. Xenobiotica 37:10-11, pages 1331-1354.
Read now
Read now
Aristides Dokoumetzidis, Lida Kalantzi & Nikoletta Fotaki. (2007) Predictive models for oral drug absorption: from in silico methods to integrated dynamical models. Expert Opinion on Drug Metabolism & Toxicology 3:4, pages 491-505.
Read now
Read now
Olavi Pelkonen. (2007) Metabolism and pharmacokinetics in children and the elderly. Expert Opinion on Drug Metabolism & Toxicology 3:2, pages 147-148.
Read now
Read now
Matt D Segall, Alan P Beresford, Joelle MR Gola, Dan Hawksley & Mike H Tarbit. (2006) Focus on success: using a probabilistic approach to achieve an optimal balance of compound properties in drug discovery. Expert Opinion on Drug Metabolism & Toxicology 2:2, pages 325-337.
Read now
Read now
Articles from other publishers (101)
Mannu Dwivedi, Padamnabhi S. Nagar, Aruna Joshi, Anjali Trivedi, Kalpna D. Rakholiya, Hedmon Okella & Mital J. Kaneria. 2024. Nanotechnology and In Silico Tools. Nanotechnology and In Silico Tools
331
347
.
Ruifang Guan, Xuening Li & Guo Ma. (2023) Prediction of pediatric dose of tirzepatide from the reference adult dose using physiologically based pharmacokinetic modelling. Frontiers in Pharmacology 14.
Crossref
Crossref
Peter N. Morcos, Jan Schlender, Rolf Burghaus, Jonathan Moss, Adam Lloyd, Barrett H. Childs, Margaret E. Macy, Joel M. Reid, John Chung & Dirk Garmann. (2023) Model‐informed approach to support pediatric dosing for the pan‐PI3K inhibitor copanlisib in children and adolescents with relapsed/refractory solid tumors. Clinical and Translational Science 16:7, pages 1197-1209.
Crossref
Crossref
Chaozhuang Shen, Wenxin Shao, Wenhui Wang, Hua Sun, Xiaohu Wang, Kuo Geng, Xingwen Wang & Haitang Xie. (2023) Physiologically based pharmacokinetic modeling of levetiracetam to predict the exposure in hepatic and renal impairment and elderly populations. CPT: Pharmacometrics & Systems Pharmacology 12:7, pages 1001-1015.
Crossref
Crossref
Panteleimon D. Mavroudis, Donato Teutonico, Alexandra Abos & Nikhil Pillai. (2023) Application of machine learning in combination with mechanistic modeling to predict plasma exposure of small molecules. Frontiers in Systems Biology 3.
Crossref
Crossref
Arham Jamaal Rajput, Hamza Khaled Abdelmajed Aldibani & Amin Rostami‐Hodjegan. (2023) In‐depth analysis of patterns in selection of different physiologically based pharmacokinetic modeling tools: Part I – Applications and rationale behind the use of open source‐code software. Biopharmaceutics & Drug Disposition 44:3, pages 274-285.
Crossref
Crossref
Luhua Liang, Wentao Li, Zhihao Zhang, Dingyuan Li, Sijing Pu, Rongwu Xiang & Fei Zhai. (2023) Develop adult extrapolation to pediatrics and pediatric dose optimization based on the physiological pharmacokinetic model of azithromycin. Biopharmaceutics & Drug Disposition 44:3, pages 245-258.
Crossref
Crossref
Mo’tasem M. Alsmadi. (2023) The investigation of the complex population-drug-drug interaction between ritonavir-boosted lopinavir and chloroquine or ivermectin using physiologically-based pharmacokinetic modeling. Drug Metabolism and Personalized Therapy 38:1, pages 87-105.
Crossref
Crossref
Chaozhuang Shen, Dahu Liang, Xiaohu Wang, Wenxin Shao, Kuo Geng, Xingwen Wang, Hua Sun & Haitang Xie. (2022) Predictive performance and verification of physiologically based pharmacokinetic model of propylthiouracil. Frontiers in Pharmacology 13.
Crossref
Crossref
Mo'tasem M. Alsmadi, Laith N. AL Eitan, Nasir M. Idkaidek & Karem H. Alzoubi. (2022) The Development of a PBPK Model for Atomoxetine Using Levels in Plasma,
Saliva and Brain Extracellular Fluid in Patients with Normal and Deteriorated
Kidney Function. CNS & Neurological Disorders - Drug Targets 21:8, pages 704-716.
Crossref
Crossref
Hongyi Yang, Leting Yang, Xiaofang Zhong, Xuehua Jiang, Liang Zheng & Ling Wang. (2022) Physiologically based pharmacokinetic modeling of brivaracetam and its interactions with rifampin based on CYP2C19 phenotypes. European Journal of Pharmaceutical Sciences 177, pages 106258.
Crossref
Crossref
Luna Prieto Garcia, Anna Lundahl, Christine Ahlström, Anna Vildhede, Hans Lennernäs & Erik Sjögren. (2022) Does the choice of applied physiologically‐based pharmacokinetics platform matter? A case study on simvastatin disposition and drug–drug interaction. CPT: Pharmacometrics & Systems Pharmacology 11:9, pages 1194-1209.
Crossref
Crossref
Wei Wang & Defang Ouyang. (2022) Opportunities and challenges of physiologically based pharmacokinetic modeling in drug delivery. Drug Discovery Today 27:8, pages 2100-2120.
Crossref
Crossref
Sebastian Frechen & Amin Rostami-Hodjegan. (2022) Quality Assurance of PBPK Modeling Platforms and Guidance on Building, Evaluating, Verifying and Applying PBPK Models Prudently under the Umbrella of Qualification: Why, When, What, How and By Whom?. Pharmaceutical Research 39:8, pages 1733-1748.
Crossref
Crossref
Jacqueline G. Gerhart, Fernando O. Carreño, Matthew Shane Loop, Craig R. Lee, Andrea N. Edginton, Jaydeep Sinha, Karan R. Kumar, Carl M. Kirkpatrick, Christoph P. Hornik & Daniel Gonzalez. (2022) Use of Real‐World Data and Physiologically‐Based Pharmacokinetic Modeling to Characterize Enoxaparin Disposition in Children With Obesity. Clinical Pharmacology & Therapeutics 112:2, pages 391-403.
Crossref
Crossref
Samuel Dubinsky, Paul Malik, Dagmar M. Hajducek & Andrea Edginton. (2022) Determining the Effects of Chronic Kidney Disease on Organic Anion Transporter1/3 Activity Through Physiologically Based Pharmacokinetic Modeling. Clinical Pharmacokinetics 61:7, pages 997-1012.
Crossref
Crossref
Abdulkarim Najjar, Andreas Schepky, Christopher-Tilman Krueger, Matthew Dent, Sophie Cable, Hequn Li, Sebastien Grégoire, Laurene Roussel, Audrey Noel-Voisin, Nicola J. Hewitt & Estefania Cardamone. (2022) Use of Physiologically-Based Kinetics Modelling to Reliably Predict Internal Concentrations of the UV Filter, Homosalate, After Repeated Oral and Topical Application. Frontiers in Pharmacology 12.
Crossref
Crossref
Manuel Ibarra, Alejandra Schiavo & Lawrence J. Lesko. 2022. The ADME Encyclopedia. The ADME Encyclopedia
987
995
.
Sheila Annie Peters. 2021. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulations. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulations
541
546
.
Sheila Annie Peters. 2021. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulations. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulations
535
540
.
Sheila Annie Peters. 2021. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulations. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulations
527
533
.
Sheila Annie Peters. 2021. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulations. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulations
521
525
.
Sheila Annie Peters. 2021. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulations. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulations
515
520
.
Sheila Annie Peters. 2021. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulations. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulations
509
513
.
Sheila Annie Peters. 2021. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulations. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulations
561
566
.
Sheila Annie Peters. 2021. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulations. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulations
555
559
.
Sheila Annie Peters. 2021. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulations. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulations
547
553
.
Sonja E. Zapke, Stefan Willmann, Scott-Oliver Grebe, Kristin Menke, Petra A. Thürmann & Sven Schmiedl. (2021) Comparing Predictions of a PBPK Model for Cyclosporine With Drug Levels From Therapeutic Drug Monitoring. Frontiers in Pharmacology 12.
Crossref
Crossref
Frederico S. Martins, Peijuan Zhu, M. Tobias Heinrichs & Sherwin K. B. Sy. (2020) Physiologically based pharmacokinetic‐pharmacodynamic evaluation of meropenem plus fosfomycin in paediatrics. British Journal of Clinical Pharmacology 87:3, pages 1012-1023.
Crossref
Crossref
Manuel Ibarra, Alejandra Schiavo & Lawrence J. Lesko. 2021. The ADME Encyclopedia. The ADME Encyclopedia
1
9
.
Paul R.V. Malik, Cindy H.T. Yeung, Shams Ismaeil, Urooj Advani, Sebastian Djie & Andrea N. Edginton. (2020) A Physiological Approach to Pharmacokinetics in Chronic Kidney Disease. The Journal of Clinical Pharmacology 60:S1.
Crossref
Crossref
Kiersten Utsey, Madeleine S. Gastonguay, Sean Russell, Reed Freling, Matthew M. Riggs & Ahmed Elmokadem. (2020) Quantification of the Impact of Partition Coefficient Prediction Methods on Physiologically Based Pharmacokinetic Model Output Using a Standardized Tissue Composition. Drug Metabolism and Disposition 48:10, pages 903-916.
Crossref
Crossref
Piyush Bajaj, Rosalinde Masereeuw, J. Eric McDuffie & Matthew P. Wagoner. 2020. Identification and Quantification of Drugs, Metabolites, Drug Metabolizing Enzymes, and Transporters. Identification and Quantification of Drugs, Metabolites, Drug Metabolizing Enzymes, and Transporters
507
534
.
Nina Isoherranen & Robert S. Foti. 2020. Identification and Quantification of Drugs, Metabolites, Drug Metabolizing Enzymes, and Transporters. Identification and Quantification of Drugs, Metabolites, Drug Metabolizing Enzymes, and Transporters
273
309
.
Jim H. Hughes, Richard N. Upton, Stephanie E. Reuter, Darlene M. Rozewski, Mitch A. Phelps & David J. R. Foster. (2019) Development of a physiologically based pharmacokinetic model for intravenous lenalidomide in mice. Cancer Chemotherapy and Pharmacology 84:5, pages 1073-1087.
Crossref
Crossref
Mo'tasem M. Alsmadi, Mahdi Qasem Alfarah, Jawaher Albderat, Ghazi Alsalaita, Reham AlMardini, Salim Hamadi, Ahmad Al‐Ghazawi, Omar Abu‐Duhair & Nasir Idkaidek. (2019) The development of a population physiologically based pharmacokinetic model for mycophenolic mofetil and mycophenolic acid in humans using data from plasma, saliva, and kidney tissue. Biopharmaceutics & Drug Disposition 40:9, pages 325-340.
Crossref
Crossref
Stefan Willmann, Matthias Frei, Gabriele Sutter, Katrin Coboeken, Thomas Wendl, Thomas Eissing, Jörg Lippert & Heino Stass. (2019)
Application of Physiologically‐Based and Population
Pharmacokinetic
Modeling for Dose Finding and Confirmation During the Pediatric Development of Moxifloxacin
. CPT: Pharmacometrics & Systems Pharmacology 8:9, pages 654-663.
Crossref
Crossref
Ramesh Kumar, Amit Kumar Singh, Ashutosh Gupta & Abhay K. Pandey. 2019. Phytochemistry: An in-silico and in-vitro Update. Phytochemistry: An in-silico and in-vitro Update
479
490
.
Fan Yi, Li Li, Li-jia Xu, Hong Meng, Yin-mao Dong, Hai-bo Liu & Pei-gen Xiao. (2018) In silico approach in reveal traditional medicine plants pharmacological material basis. Chinese Medicine 13:1.
Crossref
Crossref
Jan-Frederik Schlender, Donato Teutonico, Katrin Coboeken, Katrin Schnizler, Thomas Eissing, Stefan Willmann, Ulrich Jaehde & Heino Stass. (2018) A Physiologically-Based Pharmacokinetic Model to Describe Ciprofloxacin Pharmacokinetics Over the Entire Span of Life. Clinical Pharmacokinetics 57:12, pages 1613-1634.
Crossref
Crossref
Christoph Niederalt, Lars Kuepfer, Juri Solodenko, Thomas Eissing, Hans-Ulrich Siegmund, Michael Block, Stefan Willmann & Jörg Lippert. (2017) A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-Sim. Journal of Pharmacokinetics and Pharmacodynamics 45:2, pages 235-257.
Crossref
Crossref
Panteleimon D. Mavroudis, Helen E. Hermes, Donato Teutonico, Thomas G. Preuss & Sebastian Schneckener. (2018) Development and validation of a physiology-based model for the prediction of pharmacokinetics/toxicokinetics in rabbits. PLOS ONE 13:3, pages e0194294.
Crossref
Crossref
Nadine Schaefer, Daniel Moj, Thorsten Lehr, Peter H. Schmidt & Frank Ramsthaler. (2017) The feasibility of physiologically based pharmacokinetic modeling in forensic medicine illustrated by the example of morphine. International Journal of Legal Medicine 132:2, pages 415-424.
Crossref
Crossref
Daniel Moj, Hannah Britz, Jürgen Burhenne, Clinton F. Stewart, Gerlinde Egerer, Walter E. Haefeli & Thorsten Lehr. (2017) A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat for pediatric and adult patients and its application for dose specification. Cancer Chemotherapy and Pharmacology 80:5, pages 1013-1026.
Crossref
Crossref
S Pilari, T Gaub, M Block & L Görlitz. (2017) Development of Physiologically Based Organ Models to Evaluate the Pharmacokinetics of Drugs in the Testes and the Thyroid Gland. CPT: Pharmacometrics & Systems Pharmacology 6:8, pages 532-542.
Crossref
Crossref
Markus Krauss, Ute Hofmann, Clemens Schafmayer, Svitlana Igel, Jan Schlender, Christian Mueller, Mario Brosch, Witigo von Schoenfels, Wiebke Erhart, Andreas Schuppert, Michael Block, Elke Schaeffeler, Gabriele Boehmer, Linus Goerlitz, Jan Hoecker, Joerg Lippert, Reinhold Kerb, Jochen Hampe, Lars Kuepfer & Matthias Schwab. (2017) Translational learning from clinical studies predicts drug pharmacokinetics across patient populations. npj Systems Biology and Applications 3:1.
Crossref
Crossref
Christoph Thiel, Henrik Cordes, Lorenzo Fabbri, Hélène Eloise Aschmann, Vanessa Baier, Ines Smit, Francis Atkinson, Lars Mathias Blank & Lars Kuepfer. (2017) A Comparative Analysis of Drug-Induced Hepatotoxicity in Clinically Relevant Situations. PLOS Computational Biology 13:2, pages e1005280.
Crossref
Crossref
Jan-Frederik Schlender, Michaela Meyer, Kirstin Thelen, Markus Krauss, Stefan Willmann, Thomas Eissing & Ulrich Jaehde. (2016) Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals. Clinical Pharmacokinetics 55:12, pages 1573-1589.
Crossref
Crossref
L Kuepfer, C Niederalt, T Wendl, J‐F Schlender, S Willmann, J Lippert, M Block, T Eissing & D Teutonico. (2016) Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model. CPT: Pharmacometrics & Systems Pharmacology 5:10, pages 516-531.
Crossref
Crossref
Diana White, Dennis Coombe, Vahid Rezania & Jack Tuszynski. (2016) Building a 3D Virtual Liver: Methods for Simulating Blood Flow and Hepatic Clearance on 3D Structures. PLOS ONE 11:9, pages e0162215.
Crossref
Crossref
J. Gerry Kenna, Mikael Persson, Scott Q. Siler, Ke Yu, Chuchu Hu, Minjun Chen, Joshua Xu, Weida Tong, Yvonne Will & Michael D. Aleo. 2016. Drug Discovery Toxicology. Drug Discovery Toxicology
93
129
.
Dharmendra Yadav, Reeta Rai, Ramendra Pratap & Harpreet Singh. 2016. Chemometrics Applications and Research. Chemometrics Applications and Research
33
99
.
Lars Kuepfer, Christoph Niederalt, Thomas Wendl, Jan-Frederik Schlender, Michael Block, Thomas Eissing & Donato Teutonico. 2016. Intracellular Delivery III. Intracellular Delivery III
363
374
.
Markus Krauss, Kai Tappe, Andreas Schuppert, Lars Kuepfer & Linus Goerlitz. (2015) Bayesian Population Physiologically-Based Pharmacokinetic (PBPK) Approach for a Physiologically Realistic Characterization of Interindividual Variability in Clinically Relevant Populations. PLOS ONE 10:10, pages e0139423.
Crossref
Crossref
James M. Gallo & Marc R. Birtwistle. (2015) Network pharmacodynamic models for customized cancer therapy. WIREs Systems Biology and Medicine 7:4, pages 243-251.
Crossref
Crossref
Jörg Lippert, Rolf Burghaus, Lars Kuepfer, Bart Ploeger, Stephan Schaller, Walter Schmitt & Stefan Willmann. 2016. New Approaches to Drug Discovery. New Approaches to Drug Discovery
313
329
.
Christoph Thiel, Sebastian Schneckener, Markus Krauss, Ahmed Ghallab, Ute Hofmann, Tobias Kanacher, Sebastian Zellmer, Rolf Gebhardt, Jan G. Hengstler & Lars Kuepfer. (2015) A Systematic Evaluation of the Use of Physiologically Based Pharmacokinetic Modeling for Cross-Species Extrapolation. Journal of Pharmaceutical Sciences 104:1, pages 191-206.
Crossref
Crossref
C. Markopoulos, F. Thoenen, D. Preisig, M. Symillides, M. Vertzoni, N. Parrott, C. Reppas & G. Imanidis. (2014) Biorelevant media for transport experiments in the Caco-2 model to evaluate drug absorption in the fasted and the fed state and their usefulness. European Journal of Pharmaceutics and Biopharmaceutics 86:3, pages 438-448.
Crossref
Crossref
Lars Ole Schwen, Markus Krauss, Christoph Niederalt, Felix Gremse, Fabian Kiessling, Andrea Schenk, Tobias Preusser & Lars Kuepfer. (2014) Spatio-Temporal Simulation of First Pass Drug Perfusion in the Liver. PLoS Computational Biology 10:3, pages e1003499.
Crossref
Crossref
Henrik Cordes, Christoph Thiel, Lars M. Blank & Lars Küpfer. (2014) Modellierung metabolischer Netzwerke im menschlichen Körper. BIOspektrum 20:1, pages 39-41.
Crossref
Crossref
Winnie Vogt. (2013) Evaluation and Optimisation of Current Milrinone Prescribing for the Treatment and Prevention of Low Cardiac Output Syndrome in Paediatric Patients After Open Heart Surgery Using a Physiology-Based Pharmacokinetic Drug–Disease Model. Clinical Pharmacokinetics 53:1, pages 51-72.
Crossref
Crossref
Stefan Willmann, Corina Becker, Rolf Burghaus, Katrin Coboeken, Andrea Edginton, Jörg Lippert, Hans-Ulrich Siegmund, Kirstin Thelen & Wolfgang Mück. (2013) Development of a Paediatric Population-Based Model of the Pharmacokinetics of Rivaroxaban. Clinical Pharmacokinetics 53:1, pages 89-102.
Crossref
Crossref
Christian Wagner, Kirstin Thelen, Stefan Willmann, Arzu Selen & Jennifer B. Dressman. (2013) Utilizing In Vitro and PBPK Tools to Link ADME Characteristics to Plasma Profiles: Case Example Nifedipine Immediate Release Formulation. Journal of Pharmaceutical Sciences 102:9, pages 3205-3219.
Crossref
Crossref
Nadia Quignot. (2013) Modeling bioavailability to organs protected by biological barriers. In Silico Pharmacology 1:1.
Crossref
Crossref
J Lippert, M Brosch, O von Kampen, M Meyer, H.‐U Siegmund, C Schafmayer, T Becker, B Laffert, L Görlitz, S Schreiber, PJ Neuvonen, M Niemi, J Hampe & L Kuepfer. (2012) A Mechanistic, Model‐Based Approach to Safety Assessment in Clinical Development. CPT: Pharmacometrics & Systems Pharmacology 1:11, pages 1-8.
Crossref
Crossref
Alexander V. LyubimovGillian C. Wallace, Diane B. Ramsden & M. Helen Grant. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
47
.
Neil R. Mathias & John Crison. (2012) The Use of Modeling Tools to Drive Efficient Oral Product Design. The AAPS Journal 14:3, pages 591-600.
Crossref
Crossref
Frank Dickmann, Jürgen Falkner, Wilfried Gunia, Jochen Hampe, Michael Hausmann, Alexander Herrmann, Nick Kepper, Tobias A. Knoch, Svenja Lauterbach, Jörg Lippert, Kathrin Peter, Eberhard Schmitt, Ulrich Schwardmann, Juri Solodenko, Dietmar Sommerfeld, Thomas Steinke, Anette Weisbecker & Ulrich Sax. (2012) Solutions for biomedical grid computing—Case studies from the D-Grid project Services@MediGRID. Journal of Computational Science 3:5, pages 280-297.
Crossref
Crossref
Michaela Meyer, Sebastian Schneckener, Bernd Ludewig, Lars Kuepfer & Joerg Lippert. (2012) Using Expression Data for Quantification of Active Processes in Physiologically Based Pharmacokinetic Modeling. Drug Metabolism and Disposition 40:5, pages 892-901.
Crossref
Crossref
Bilal S. Abuasal, Michael B. Bolger, Don K. WalkerAmal Kaddoumi. (2012)
In Silico
Modeling for the Nonlinear Absorption Kinetics of UK-343,664: A P-gp and CYP3A4 Substrate
. Molecular Pharmaceutics 9:3, pages 492-504.
Crossref
Crossref
Kirstin Thelen, Katrin Coboeken, Stefan Willmann, Jennifer B. Dressman & Jörg Lippert. (2012) Evolution of a Detailed Physiological Model to Simulate the Gastrointestinal Transit and Absorption Process in Humans, Part II: Extension to Describe Performance of Solid Dosage Forms. Journal of Pharmaceutical Sciences 101:3, pages 1267-1280.
Crossref
Crossref
Olaf Weber, Stefan Willmann, Hilmar Bischoff, Volkhart Li, Alexandros Vakalopoulos, Klemens Lustig, Frank-Thorsten Hafner, Roland Heinig, Carsten Schmeck & Klaus Buehner. (2012) Prediction of a potentially effective dose in humans for BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein (CETP) by allometric species scaling and combined pharmacodynamic and physiologically-based pharmacokinetic modelling. British Journal of Clinical Pharmacology 73:2, pages 219-231.
Crossref
Crossref
Gisela Kersting, Stefan Willmann, Gudrun Würthwein, Jörg Lippert, Joachim Boos & Georg Hempel. (2011) Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children. Cancer Chemotherapy and Pharmacology 69:2, pages 397-405.
Crossref
Crossref
Lars Kuepfer, Jörg Lippert & Thomas Eissing. 2012. Advances in Systems Biology. Advances in Systems Biology
543
561
.
Kirstin Thelen, Katrin Coboeken, Stefan Willmann, Rolf Burghaus, Jennifer B. Dressman & Jörg Lippert. (2011) Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, Part 1: Oral solutions. Journal of Pharmaceutical Sciences 100:12, pages 5324-5345.
Crossref
Crossref
. (2011) A Generic, Cross-Chemical Predictive PBTK Model with Multiple Entry Routes Running as Application in MS Excel; Design of the Model and Comparison of Predictions with Experimental Results. The Annals of Occupational Hygiene.
Crossref
Crossref
Feras Khalil & Stephanie Läer. (2011) Physiologically Based Pharmacokinetic Modeling: Methodology, Applications, and Limitations with a Focus on Its Role in Pediatric Drug Development. Journal of Biomedicine and Biotechnology 2011, pages 1-13.
Crossref
Crossref
Yi Gao, Robert A. Carr, Julie K. Spence, Weili W. Wang, Teresa M. Turner, John M. Lipari & Jonathan M. Miller. (2010) A pH-Dilution Method for Estimation of Biorelevant Drug Solubility along the Gastrointestinal Tract: Application to Physiologically Based Pharmacokinetic Modeling. Molecular Pharmaceutics 7:5, pages 1516-1526.
Crossref
Crossref
Yasushi Shono, Ekarat Jantratid, Filippos Kesisoglou, Christos Reppas & Jennifer B. Dressman. (2010) Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans. European Journal of Pharmaceutics and Biopharmaceutics 76:1, pages 95-104.
Crossref
Crossref
Kirstin Thelen, Ekarat Jantratid, Jennifer B. Dressman, Jorg Lippert & Stefan Willmann. (2010) Analysis of Nifedipine Absorption from Soft Gelatin Capsules Using PBPK Modeling and Biorelevant Dissolution Testing. Journal of Pharmaceutical Sciences 99:6, pages 2899-2904.
Crossref
Crossref
Stefan Willmann, Andrea N Edginton, Marcus Kleine-Besten, Ekarat Jantratid, Kirstin Thelen & Jennifer B Dressman. (2009) Whole-body physiologically based pharmacokinetic population modelling of oral drug administration: inter-individual variability of cimetidine absorption. Journal of Pharmacy and Pharmacology 61:7, pages 891-899.
Crossref
Crossref
Akihiro Hisaka, Yoshiyuki Ohno, Takehito Yamamoto & Hiroshi Suzuki. (2010) Theoretical Considerations on Quantitative Prediction of Drug-Drug Interactions. Drug Metabolism and Pharmacokinetics 25:1, pages 48-61.
Crossref
Crossref
Matthew J Winter, Stewart F Owen, Richard Murray‐Smith, Grace H Panter, Malcolm J Hetheridge & Lewis B Kinter. (2009) Using data from drug discovery and development to aid the aquatic environmental risk assessment of human pharmaceuticals: Concepts, considerations, and challenges. Integrated Environmental Assessment and Management 6:1, pages 38-51.
Crossref
Crossref
Peter Thygesen, Panos Macheras & Achiel Van Peer. (2009) Physiologically-Based PK/PD Modelling of Therapeutic Macromolecules. Pharmaceutical Research 26:12, pages 2543-2550.
Crossref
Crossref
Derek P. Reynolds, Kiril Lanevskij, Pranas Japertas, Remigijus Didziapetris & Alanas Petrauskas. (2009) Ionization-specific analysis of human intestinal absorption. Journal of Pharmaceutical Sciences 98:11, pages 4039-4054.
Crossref
Crossref
Yasushi Shono, Ekarat Jantratid, Niels Janssen, Filippos Kesisoglou, Yun Mao, Maria Vertzoni, Christos Reppas & Jennifer B. Dressman. (2009) Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling. European Journal of Pharmaceutics and Biopharmaceutics 73:1, pages 107-114.
Crossref
Crossref
Kiyohiko Sugano, Lourdes Cucurull‐Sanchez & Joanne Bennett. 2009. Hit and Lead Profiling. Hit and Lead Profiling
117
143
.
Stephanie Läer, Jeffrey S. Barrett & Bernd Meibohm. (2009) The In Silico Child: Using Simulation to Guide Pediatric Drug Development and Manage Pediatric Pharmacotherapy. The Journal of Clinical Pharmacology 49:8, pages 889-904.
Crossref
Crossref
Andrea N. EdgintonLen Ritter. (2009) Predicting Plasma Concentrations of Bisphenol A in Children Younger Than 2 Years of Age after Typical Feeding Schedules, using a Physiologically Based Toxicokinetic Model. Environmental Health Perspectives 117:4, pages 645-652.
Crossref
Crossref
Andrea N. Edginton, Gertrud Ahr, Stefan Willmann & Heino Stass. (2009) Defining the Role of Macrophages in Local Moxifloxacin Tissue Concentrations using Biopsy Data and Whole-Body Physiologically Based Pharmacokinetic Modelling. Clinical Pharmacokinetics 48:3, pages 181-187.
Crossref
Crossref
F. Bouzom & B. Walther. (2008) Pharmacokinetic predictions in children by using the physiologically based pharmacokinetic modelling. Fundamental & Clinical Pharmacology 22:6, pages 579-587.
Crossref
Crossref
Han van de Waterbeemd. 2008. Drug Bioavailability. Drug Bioavailability
69
99
.
Andrea N Edginton & Stefan Willmann. (2008) Physiology-Based Simulations of a Pathological Condition. Clinical Pharmacokinetics 47:11, pages 743-752.
Crossref
Crossref
Jennifer B Dressman, Kirstin Thelen & Ekarat Jantratid. (2008) Towards Quantitative Prediction of Oral Drug Absorption. Clinical Pharmacokinetics 47:10, pages 655-667.
Crossref
Crossref
Michaela Vossen, Michael Sevestre, Christoph Niederalt, In-Jin Jang, Stefan Willmann & Andrea N Edginton. (2007) Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models. Theoretical Biology and Medical Modelling 4:1.
Crossref
Crossref
Max von Kleist & Wilhelm Huisinga. (2007) Physiologically based pharmacokinetic modelling: a sub-compartmentalized model of tissue distribution. Journal of Pharmacokinetics and Pharmacodynamics 34:6, pages 789-806.
Crossref
Crossref
Han van de Waterbeemd. 2007. Molecular Drug Properties. Molecular Drug Properties
25
52
.
Stefan Willmann, Andrea N. Edginton & Jennifer B. Dressman. (2007) Development and Validation of a Physiology-based Model for the Prediction of Oral Absorption in Monkeys. Pharmaceutical Research 24:7, pages 1275-1282.
Crossref
Crossref
Stefan Willmann, Karsten Höhn, Andrea Edginton, Michael Sevestre, Juri Solodenko, Wolfgang Weiss, Jörg Lippert & Walter Schmitt. (2007) Development of a Physiology-Based Whole-Body Population Model for Assessing the Influence of Individual Variability on the Pharmacokinetics of Drugs. Journal of Pharmacokinetics and Pharmacodynamics 34:3, pages 401-431.
Crossref
Crossref
Ian S. Haworth. (2006) Computational drug delivery. Advanced Drug Delivery Reviews 58:12-13, pages 1271-1273.
Crossref
Crossref
Andrea N Edginton, Walter Schmitt & Stefan Willmann. (2006) Development and Evaluation of a Generic Physiologically Based Pharmacokinetic Model for Children. Clinical Pharmacokinetics 45:10, pages 1013-1034.
Crossref
Crossref